Karin Stålberg

ORCID: 0000-0001-5527-8796 · 8 papers in corpus
other 2026
Molecular cancer ·doi:10.1186/s12943-026-02654-1

BACKGROUND: Sensitive and specific blood biomarkers for early detection of colorectal (CRC), lung (LuCa) and ovarian (OvCa) cancers are highly warranted. The current blood tests often need to be complemented with other clinical methods to a…

diagnostic-accuracy 2025
Communications medicine ·doi:10.1038/s43856-025-00945-0

BACKGROUND: Ovarian cancer has the highest mortality of all gynecological cancers and surgery is commonly used as final diagnostic. Available literature indicates that women with benign tumors could often be conservatively managed, but accu…

diagnostic-accuracy 2024
Scientific reports ·doi:10.1038/s41598-024-68249-2

Ovarian cancer is the 8th most common cancer among women and has a 5-year survival of only 30-50%. While the survival is close to 90% for stage I tumours it is only 20% for stage IV. Current biomarkers are not sensitive nor specific enough,…

diagnostic-accuracy 2024
iScience ·doi:10.1016/j.isci.2024.109001

Early detection is key for increased survival in ovarian cancer, but no general screening program exists today due to lack of biomarkers and overall cost versus benefit over traditional clinical methods. Here, we used dried cervico-vaginal …

diagnostic-accuracy 2022
Communications medicine ·doi:10.1038/s43856-022-00193-6

BACKGROUND: Ovarian cancer is the eighth most common cancer among women and due to late detection prognosis is poor with an overall 5-year survival of 30-50%. Novel biomarkers are needed to reduce diagnostic surgery and enable detection of …

observational 2022
Acta obstetricia et gynecologica Scandinavica ·doi:10.1111/aogs.14385

INTRODUCTION: Minimally invasive methods to reduce menorrhagia were introduced in the 1980s and 1990s. Transcervical endometrial resection (TCRE) and endometrial ablation (EA) are two of the most frequently used methods. As none of them can…

diagnostic-accuracy 2022
Cancers ·doi:10.3390/cancers14071757

BACKGROUND: Ovarian cancer is the eighth most common cancer among women and has a 5-year survival of only 30-50%. The survival is close to 90% for patients in stage I but only 20% for patients in stage IV. The presently available biomarkers…

diagnostic-accuracy 2018
Clinical proteomics ·doi:10.1186/s12014-018-9216-y

BACKGROUND: Over 500,000 women worldwide are diagnosed with ovarian or endometrial cancer each year. We have used a two-step strategy to identify plasma proteins that could be used to improve the diagnosis of women with an indication of gyn…